Your browser doesn't support javascript.
loading
PILE: a candidate prognostic score in cancer patients treated with immunotherapy.
Guven, D C; Yildirim, H C; Bilgin, E; Aktepe, O H; Taban, H; Sahin, T K; Cakir, I Y; Akin, S; Dizdar, O; Aksoy, S; Yalcin, S; Erman, M; Kilickap, S.
Afiliação
  • Guven DC; Hacettepe University Cancer Institute, Ankara, Turkey. denizcguven@hotmail.com.
  • Yildirim HC; Department of Medical Oncology, Hacettepe University Cancer Institute, 06100, Sihhiye, Ankara, Turkey. denizcguven@hotmail.com.
  • Bilgin E; Hacettepe University Cancer Institute, Ankara, Turkey.
  • Aktepe OH; Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Taban H; Hacettepe University Cancer Institute, Ankara, Turkey.
  • Sahin TK; Hacettepe University Cancer Institute, Ankara, Turkey.
  • Cakir IY; Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Akin S; Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Dizdar O; Hacettepe University Cancer Institute, Ankara, Turkey.
  • Aksoy S; Hacettepe University Cancer Institute, Ankara, Turkey.
  • Yalcin S; Hacettepe University Cancer Institute, Ankara, Turkey.
  • Erman M; Hacettepe University Cancer Institute, Ankara, Turkey.
  • Kilickap S; Hacettepe University Cancer Institute, Ankara, Turkey.
Clin Transl Oncol ; 23(8): 1630-1636, 2021 Aug.
Article em En | MEDLINE | ID: mdl-33586122
BACKGROUND: Although the immune checkpoint inhibitors (ICIs) became a vital part of cancer care, many patients do not respond to treatment, indicating need for biomarkers. The Pan-Immune-Inflammation Value (PIV) is a recently developed peripheral blood count-based biomarker. Herein, we evaluated a PIV-based candidate scoring system as a prognostic biomarker in ICI-treated patients. METHODS: A total of 120 advanced cancer patients treated with anti-PD-1 or anti-PD-L1 inhibitors for any cancer type were included in this study. The PILE scoring system incorporating the PIV (< median vs. ≥ median), lactate dehydrogenase levels (normal vs. > normal) and Eastern Cooperative Oncology Group performance status (0 vs. ≥ 1) was constructed from the multivariate analyses and used for stratification. The association between overall survival (OS), progression-free survival and PILE risk category was evaluated with multivariate analysis. RESULTS: The median follow-up was 9.62 months and the median OS of all cohort were 12.42 ± 2.75 months. Patients with higher PIV had significantly decreased OS (7.75 ± 1.64 vs. 18.63 ± 4.26 months, p = 0.037). The patients in the PILE high-risk group (PILE score 2-3) had decreased OS (18.63 ± 4.02 vs. 5.09 ± 1.23 months, HR: 2.317, 95% CI: 1.450-3.700, p < 0.001) and PFS (7.69 ± 1.30 vs. 2.69 ± 0.65 months, HR: 1.931, 95% CI: 1.263-2.954, p = 0.002) compared to PILE low-risk group (PILE score 0-1). The Harrell C-Index values were 0.65 and 0.61 for OS and PFS prediction, respectively. CONCLUSION: In this study, we demonstrated a decreased overall survival in ICI-treated patients with a higher PILE score. If prospective studies validate our results, PILE score could be a biomarker for immunotherapy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Checkpoint Imunológico / Imunoterapia / Neoplasias Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Checkpoint Imunológico / Imunoterapia / Neoplasias Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article